4//SEC Filing
Bellinger Andrew 4
Accession 0001209191-22-043018
CIK 0001840574other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 5:00 PM ET
Size
8.6 KB
Accession
0001209191-22-043018
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-07-20$1.39/sh+20,000$27,800→ 26,629 total - Exercise/Conversion
Stock Option (right to buy)
2022-07-20−20,000→ 1,599 totalExercise: $1.39Exp: 2029-06-24→ Common Stock (20,000 underlying) - Sale
Common Stock
2022-07-20$34.90/sh−20,000$698,000→ 6,629 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2022.
- [F2]The option was granted on June 25, 2019 for 21,599 shares. The shares underlying the option vested on May 1, 2020.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001864116
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 5:00 PM ET
- Size
- 8.6 KB